Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Progen Pharmaceuticals Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Progen Pharmaceuticals Limited - Product Pipeline Review - 2014', provides an overview of the Progen Pharmaceuticals Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Progen Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Progen Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Progen Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Progen Pharmaceuticals Limited's pipeline products Reasons to buy - Evaluate Progen Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Progen Pharmaceuticals Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Progen Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Progen Pharmaceuticals Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progen Pharmaceuticals Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Progen Pharmaceuticals Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Progen Pharmaceuticals Limited Snapshot 5 Progen Pharmaceuticals Limited Overview 5 Key Information 5 Key Facts 5 Progen Pharmaceuticals Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Progen Pharmaceuticals Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Progen Pharmaceuticals Limited - Pipeline Products Glance 11 Progen Pharmaceuticals Limited - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Progen Pharmaceuticals Limited - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Progen Pharmaceuticals Limited - Drug Profiles 15 muparfostat 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 PG-11047 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PG-545 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PG-11000 Series 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PG-11100 Series 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PG-11144 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 PG-11157 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PG-11158 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PG-11159 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PG-11160 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecules Targeting HDAC and LSD-1 for Oncology 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules Targeting Heparanase for Oncology 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules Targeting LSD-1 for Oncology 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Progen Pharmaceuticals Limited - Pipeline Analysis 30 Progen Pharmaceuticals Limited - Pipeline Products by Target 30 Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration 32 Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type 33 Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 34 Progen Pharmaceuticals Limited - Recent Pipeline Updates 36 Progen Pharmaceuticals Limited - Dormant Projects 39 Progen Pharmaceuticals Limited - Discontinued Pipeline Products 40 Discontinued Pipeline Product Profiles 40 PG-562 40 muparfostat 40 Progen Pharmaceuticals Limited - Company Statement 41 Progen Pharmaceuticals Limited - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables Progen Pharmaceuticals Limited, Key Information 5 Progen Pharmaceuticals Limited, Key Facts 5 Progen Pharmaceuticals Limited - Pipeline by Indication, 2014 8 Progen Pharmaceuticals Limited - Pipeline by Stage of Development, 2014 9 Progen Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014 10 Progen Pharmaceuticals Limited - Phase III, 2014 11 Progen Pharmaceuticals Limited - Phase I, 2014 12 Progen Pharmaceuticals Limited - Preclinical, 2014 13 Progen Pharmaceuticals Limited - Discovery, 2014 14 Progen Pharmaceuticals Limited - Pipeline by Target, 2014 31 Progen Pharmaceuticals Limited - Pipeline by Route of Administration, 2014 32 Progen Pharmaceuticals Limited - Pipeline by Molecule Type, 2014 33 Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2014 35 Progen Pharmaceuticals Limited - Recent Pipeline Updates, 2014 36 Progen Pharmaceuticals Limited - Dormant Developmental Projects,2014 39 Progen Pharmaceuticals Limited - Discontinued Pipeline Products, 2014 40 Progen Pharmaceuticals Limited, Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
